Iridium (IRMD) | Financial Analysis & Statements
Iridium Corporation Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
22.7M
Gross Profit
17.0M
75.06%
Operating Income
7.1M
31.26%
Net Income
6.4M
28.39%
EPS (Diluted)
$0.50
Balance Sheet Metrics
Total Assets
108.8M
Total Liabilities
14.2M
Shareholders Equity
94.6M
Debt to Equity
0.15
Cash Flow Metrics
Operating Cash Flow
9.7M
Free Cash Flow
5.5M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Iridium Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 83.8M | 73.2M | 65.6M | 53.3M | 41.8M |
| Cost of Goods Sold | 19.5M | 16.9M | 15.4M | 12.0M | 9.8M |
| Gross Profit | 64.3M | 56.3M | 50.2M | 41.3M | 32.0M |
| Gross Margin % | 76.7% | 76.9% | 76.5% | 77.4% | 76.6% |
| Operating Expenses | |||||
| Research & Development | 3.0M | 2.8M | 2.9M | 2.3M | 1.9M |
| Selling, General & Administrative | 35.2M | 31.6M | 27.3M | 23.4M | 20.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 38.2M | 34.4M | 30.1M | 25.7M | 22.2M |
| Operating Income | 26.1M | 22.0M | 20.0M | 15.6M | 9.8M |
| Operating Margin % | 31.2% | 30.0% | 30.6% | 29.3% | 23.5% |
| Non-Operating Items | |||||
| Interest Income | 2.0M | 2.2M | 1.9M | 581.9K | 34.8K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 205.0K | 117.6K | -161.3K | -28.7K | -16.2K |
| Pre-tax Income | 28.4M | 24.3M | 21.7M | 16.2M | 9.8M |
| Income Tax | 5.9M | 5.0M | 4.5M | 3.4M | 510.8K |
| Effective Tax Rate % | 20.7% | 20.8% | 20.9% | 20.7% | 5.2% |
| Net Income | 22.5M | 19.2M | 17.2M | 12.8M | 9.3M |
| Net Margin % | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% |
| Key Metrics | |||||
| EBITDA | 27.1M | 22.8M | 21.0M | 16.3M | 11.2M |
| EPS (Basic) | $1.77 | $1.52 | $1.36 | $1.02 | $0.76 |
| EPS (Diluted) | $1.75 | $1.50 | $1.35 | $1.02 | $0.74 |
| Basic Shares Outstanding | 12722000 | 12670216 | 12602948 | 12562856 | 12346173 |
| Diluted Shares Outstanding | 12722000 | 12670216 | 12602948 | 12562856 | 12346173 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Iridium Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 51.2M | 52.2M | 49.8M | 58.0M | 62.0M |
| Short-term Investments | - | - | - | 0 | 501.9K |
| Accounts Receivable | 13.7M | 10.6M | 12.2M | 13.3M | 5.1M |
| Inventory | 11.6M | 10.4M | 12.8M | 5.4M | 4.3M |
| Other Current Assets | 4.8M | 2.0M | 1.2M | 631.0K | 1.0M |
| Total Current Assets | 81.2M | 75.2M | 76.0M | 77.5M | 76.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 154.7K | 2.0M | 2.2M | 2.5M |
| Goodwill | 3.4M | 3.1M | 2.5M | 2.1M | 1.1M |
| Intangible Assets | 3.4M | 3.1M | 2.5M | 2.1M | 1.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 333.0K | 3.0M | 2.3M | 1.3M | 966.4K |
| Total Non-Current Assets | 27.6M | 23.1M | 16.2M | 8.0M | 6.6M |
| Total Assets | 108.8M | 98.3M | 92.2M | 85.5M | 82.9M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.8M | 1.9M | 1.9M | 1.8M | 782.9K |
| Short-term Debt | - | 153.3K | 428.0K | 293.5K | 276.6K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 313.0K | 150.0K | 250.0K | - | 146.4K |
| Total Current Liabilities | 10.2M | 8.5M | 16.3M | 8.6M | 6.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 0 | 1.4K | 1.6M | 1.9M | 2.2M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 4.0M | 3.0M | 4.4M | 3.3M | 3.9M |
| Total Liabilities | 14.2M | 11.5M | 20.7M | 11.8M | 10.7M |
| Equity | |||||
| Common Stock | 1.0K | 1.3K | 1.3K | 1.3K | 1.3K |
| Retained Earnings | 64.2M | 56.8M | 43.3M | 47.3M | 47.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 94.6M | 86.8M | 71.4M | 73.7M | 72.2M |
| Key Metrics | |||||
| Total Debt | 0 | 154.7K | 2.0M | 2.2M | 2.5M |
| Working Capital | 71.0M | 66.7M | 59.7M | 68.9M | 69.4M |
Balance Sheet Composition
Iridium Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 22.5M | 19.2M | 17.2M | 12.8M | 9.3M |
| Depreciation & Amortization | 1.2M | 817.7K | 765.2K | 670.7K | 1.4M |
| Stock-Based Compensation | 2.9M | 2.5M | 2.2M | 1.4M | 1.5M |
| Working Capital Changes | -3.0M | 3.8M | -5.5M | -8.5M | -845.0K |
| Operating Cash Flow | 26.2M | 25.7M | 13.5M | 6.5M | 11.9M |
| Investing Activities | |||||
| Capital Expenditures | -7.8M | -8.0M | -7.4M | -823.0K | -482.3K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | 0 | 500.0K | 1.4M |
| Investing Cash Flow | -7.8M | -8.0M | -7.4M | -323.0K | 907.7K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -15.0M | -13.7M | -13.2M | -12.6M | 0 |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -17.6M | -14.4M | -13.8M | -12.9M | -598.8K |
| Free Cash Flow | 16.5M | 16.8M | 5.5M | 8.2M | 10.5M |
| Net Change in Cash | 878.0K | 3.3M | -7.8M | -6.7M | 12.2M |
Cash Flow Trend
Iridium Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
50.74
Forward P/E
38.28
Price to Book
12.00
Price to Sales
13.54
PEG Ratio
2.08
Profitability Ratios
Profit Margin
26.82%
Operating Margin
31.26%
Return on Equity
24.78%
Return on Assets
15.78%
Financial Health
Current Ratio
7.98
Debt to Equity
0.00
Beta
1.12
Per Share Data
EPS (TTM)
$1.75
Book Value per Share
$7.40
Revenue per Share
$6.59
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| IRMD | 1.1B | 50.74 | 12.00 | 24.78% | 26.82% | 0.00 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Axogen | 1.9B | -110.18 | 13.15 | -13.49% | -6.97% | 55.50 |
| Establishment Labs | 1.9B | -37.89 | 79.68 | -133.25% | -24.19% | 1,123.15 |
| Artivion | 1.8B | 179.71 | 4.03 | 2.70% | 2.21% | 57.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.






